ACR-2316

July 21, 2026: Acrivon Therapeutics, Inc. (NASDAQ: ACRV) announced it will give an oral presentation and present a poster at the AACR Drug Discovery and Development (AACR D3) Conference (July 21–24, 2026; Boston) highlighting its AP3 phosphoproteomics platform and ACR-2316, a clinical-stage selective WEE1/PKMYT1 inhibitor.

ACR-2316: The company will present mechanistic data showing AP3 identified a resistance mechanism to WEE1 inhibition (PKMYT1 activation leading to CDK1 Thr14 phosphorylation) and guided design of ACR-2316 to achieve sustained pathway effects (activation of CDK1, CDK2, and PLK1) intended to drive pro-apoptotic tumor cell death. ACR-2316 is in a Phase 1/2 study advancing toward dose expansion, with two weekly oral dosing regimens established. Early clinical observations include tumor shrinkage and partial responses with durable benefit in small cell lung cancer, squamous NSCLC, adenosarcoma NSCLC, and also PRs in endometrial cancer. Reported tolerability to date is characterized mainly by transient, mechanism-based neutropenia and an absence of non-hematologic adverse events.

Conference details: Oral talk July 23, 2026 (3:50–4:00 p.m. ET) and poster July 22, 2026 (6:15–8:45 p.m. ET).

Other pipeline: ACR-368 (prexasertib) is in a potentially registrational Phase 2 trial in endometrial cancer with FDA Fast Track; its OncoSignature assay has FDA Breakthrough Device designation. The company also noted early IND-enabling work on CDK11 candidates.